Application of Arsenic Trioxide-Based Combined Sequential Chemotherapy in Recurrent Resistant and Refractory Ovarian Cancers: A Single-Center, Open Phase II Clinical Study

Table 1

Patient characteristics, all patients enrolled (n = 33), and the International Federation of Gynecology and Obstetrics (FIGO).

FIGO stage	No.	%
IC	3	9%
IIA	2	6%
IIB	1	3%
IIIA	1	3%
IIIB	3	9%
IIIC	14	42%
IV	9	27%
Histology at diagnosis
High-grade serous carcinoma	26	79%
Low-grade serous carcinoma	1	3%
Mixed carcinoma (serous and endometrioid)	1	3%
Clear cell carcinoma	5	15%